Submitted:
23 September 2024
Posted:
24 September 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Case Report
4. Discussion
5. Conclusion
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kaplan, G.G.; Windsor, J.W. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology 2021, 18, 56–66. [Google Scholar] [CrossRef]
- Ng, W.K.; Wong, S.H.; Ng, S.C. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016, 14, 111–119. [Google Scholar] [CrossRef] [PubMed]
- BALL, E. Exercise guidelines for patients with inflammatory bowel disease. Gastroenterology Nursing 1998, 21, 108–111. [Google Scholar] [CrossRef] [PubMed]
- Scott, E.M.; Gaywood, I.; Scott, B.B. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. Gut 2000, 46, I1–I8. [Google Scholar] [CrossRef] [PubMed]
- Ordille, A.J.; Phadtare, S. Intensity-specific considerations for exercise for patients with inflammatory bowel disease. Gastroenterology Report 2023, 11. [Google Scholar] [CrossRef] [PubMed]
- Fagan, G.; Osborne, H.; Schultz, M. Physical activity in patients with inflammatory bowel disease: a cross-sectional study. Inflammatory Intestinal Diseases 2021, 6, 61–69. [Google Scholar] [CrossRef] [PubMed]
- Kushner, I. C-reactive protein–My perspective on its first half century, 1930-1982. Frontiers in immunology 2023, 14, 1150103. [Google Scholar] [CrossRef] [PubMed]
- Paraskevopoulos, E.; Koumantakis, G.A.; Papandreou, M. A Systematic Review of the Aerobic Exercise Program Variables for Patients with Non-Specific Neck Pain: Effectiveness and Clinical Applications. Healthcare (Basel) 2023, 11. [Google Scholar] [CrossRef]
- Ishay, Y.; Kenig, A.; Rubin, L.; Shamriz, O.; Kharouf, F. Autoimmune Diseases Induced or Exacerbated by COVID-19: A Single Center Experience. Autoimmune Dis 2022, 2022, 9171284. [Google Scholar] [CrossRef]
- Stafie, R.; Singeap, A.M.; Rotaru, A.; Stanciu, C.; Trifan, A. Bridging the gap: Unveiling the crisis of physical inactivity in inflammatory bowel diseases. World J Gastroenterol 2024, 30, 1261–1265. [Google Scholar] [CrossRef]
- Engels, M.; Cross, R.K.; Long, M.D. Exercise in patients with inflammatory bowel diseases: current perspectives. Clin Exp Gastroenterol 2018, 11, 1–11. [Google Scholar] [CrossRef]
- Protano, C.; Gallè, F.; Volpini, V.; De Giorgi, A.; Mazzeo, E.; Ubaldi, F.; Romano Spica, V.; Vitali, M.; Valeriani, F. Physical activity in the prevention and management of inflammatory bowel disease: a systematic review. Journal of Public Health 2024. [CrossRef]
- Lamers, C.R.; de Roos, N.M.; Koppelman, L.J.M.; Hopman, M.T.E.; Witteman, B.J.M. Patient experiences with the role of physical activity in inflammatory bowel disease: results from a survey and interviews. BMC Gastroenterology 2021, 21, 172. [Google Scholar] [CrossRef]
- Bilski, J.; Brzozowski, B.; Mazur-Bialy, A.; Sliwowski, Z.; Brzozowski, T. The role of physical exercise in inflammatory bowel disease. Biomed Res Int 2014, 2014, 429031. [Google Scholar] [CrossRef] [PubMed]
- Tomaschek, R.; Lampart, P.; Scheel-Sailer, A.; Gemperli, A.; Merlo, C.; Essig, S. Improvement Strategies for the Challenging Collaboration of General Practitioners and Specialists for Patients with Complex Chronic Conditions: A Scoping Review. Int J Integr Care 2022, 22, 4. [Google Scholar] [CrossRef] [PubMed]

| Date | Event/Status | Treatment/Action | Exercise Program |
|---|---|---|---|
| September 2023 | Intermittent morning diarrhea; consulted gastroenterologist. | Prescribed probiotics and rifaximin; symptoms resolved by the 4th day. | Resumed normal training and daily routine. |
| November 2023 | Diagnosed with COVID-19; experienced lethargy, dehydration, morning diarrhea, and weight loss (7 kg). | Dietary adjustments; probiotics and rifaximin prescribed again; consultation with cardiologist. | No training; remained mildly active. |
| February 2024 | In remission after budesonide treatment; calprotectin levels normalized; mucosal healing observed. | Continued budesonide treatment until remission achieved. | Hesitant to resume training; remained mildly active. |
| April 2024 | Recurrence of diarrhea (Type 5 to 7 Bristol Stool Scale); increased calprotectin levels. | Prescribed budesonide for two months; symptoms resolved after 5 days. | Resumed moderate-intensity running. |
| September 2024 | Stable bowel movements, improved appetite, high energy, reduced anxiety, and increased social engagement. | Continued budesonide treatment completed; patient in remission. | Moderate-intensity running (60-80% VO2 max) 3-4 times per week; occasional unstructured swimming. |
| Aspect | Before Exercise Regimen | After Exercise Regimen |
|---|---|---|
| Date | September 2023 - April 2024 | April 2024 - September 2024 |
| Bowel Movements | Intermittent diarrhea (Type 6-7) | Stable bowel movements (Type 1-2) |
| Calprotectin Levels | Elevated (1100 mg/gr) during active phase | Normal (41 mg/gr) during remission; increased (375 mg/gr) before resuming exercise |
| Weight | Significant weight loss (7 kg) | Stable body weight |
| Energy Levels | Low energy, fatigue, lethargy | High energy, stable even after training |
| Appetite | Reduced appetite | Improved appetite |
| Diarrhea Frequency | Frequent (up to 5 times per day) | Reduced (1-2 times per day) |
| Training Status | Limited activity; resumed mildly active | Moderate-intensity running (60-80% VO2 max) 3-4 times per week; occasional swimming |
| Psychological Well-being | Anxiety, reduced social engagement | Reduced anxiety, increased social engagement |
| Physical Activity | Minimal; cautious due to fear of worsening symptoms | Regular moderate-intensity exercise, improved fitness and functional capacity |
| Overall Disease Status | Active Crohn’s disease with intermittent symptoms | Remission with stable disease status and symptom control |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).